Q-Biologicals becomes part of Amatsigroup

January 25, 2016 News BioVox

French pharmaceutical conglomerate Amatsigroup has announced its acquisition of Q-Biologicals. Q-Biologicals was founded in 2011 as a VIB/UGent spin-off by several Innogenetics veterans and provides services in process development and biomanufacturing. Their GMP manufacturing processes of recombinant proteins, monoclonal antibodies and vaccines have successfully aided in more than 75 R&D projects.

With this consolidation, Amatsigroup continues its expansive strategy. Back in 2014 the French contract development manufacturing organization for human and veterinary pharmaceuticals also incorporated the Ghent-based SEPS Pharma into the Amatsigroup family. Now named AmatsiSEPS, the company focusses on enhanced bioavailability and oral formulation of drugs.

Former Q-Biologicals shareholders were VIB and the Flemish investment funds PMV and Fund+. The total sum of the acquisition was undisclosed.

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts


* indicates required

Intuit Mailchimp